A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis (NCT04227288) | Clinical Trial Compass
CompletedPhase 4
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
United States6 participantsStarted 2021-11-01
Plain-language summary
The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
Who can participate
Age range18 Years ā 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Must have a diagnosis of nail psoriasis in fingernail or toenails
* History of plaque psoriasis or psoriatic arthritis
* Target nail will be KOH negative for dermatophyte fungus
* Must give written informed consent prior to study procedures being conducted, also give consent to the release and use of protected health information (PHI)
* Between the ages of 18 and 85 years old
* Candidate for topical therapy in the opinion of the investigator
Exclusion Criteria:
* Males and Females unable to practice effective contraception throughout the study
* Unable to comply with the protocol
* Nursing mothers, pregnant women, and women planning to become pregnant while in this study
* Patients with erythrodermic or pustular psoriasis
* Sustained treatment to target fingernail within 6 months prior to screening
* History of trauma or surgery to target fingernail
* History of disease known to affect nails such as lichen planus, onychomycosis
* History of systemic psoriasis therapy for less than 6 months
What they're measuring
1
Clinical Improvement in Nail Thickness of Target Nail at Week 24 Compared to Baseline.